Sparks et al. Risk factors for ILD in RA patients without known ILD in ANCHOR-RA study. ILD 106/1169 participants (9.1%). Older, male, greater tobacco exposure, lower DLco, lower O2 sats, higher DAS-28-ESR, crackles on lung auscultation, MUC5B. @RheumNow #ACR26 Abstr#2884 https://t.co/73y3UJRXXk

Wang et al. Combinations of clinical factors and MUC5B to predict subclinical or undiagnosed RA-ILD @RheumNow #ACR26 Abstr#2883 https://t.co/ItP43GD30Z

If #rituximab doesn’t improve #mrRSS #skin #score at 1 yr; unlikely to improve in Yr 2 in #SSc Didn’t matter if sustained B cell depletion and Rx effect Strange as I think mRSS can still work in Y2 Rx in #scleroderma #dcSSc but with some effect in yr1 #2906 #ACR26 @RheumNow https://t.co/5pEy45W6uh

ACR 2025 SLE guidelines on the management of haematological manifestations of the condition #SLE #ACR26 @RheumNow https://t.co/RmoALrntz3

Composite endpoint to see if #scleroderma #SSc can be treated by #nerandomilast Beyond #PPF Complicated as so many organs and many different progression rates for various organs A #basket #trial of #outcomes? Novel outcomes will be used Abst#2905 @ACRheum @RheumNow #ACR26 https://t.co/lQwqqRh1q4

NO small feat! A nanoparticle target of Myeloid inhibiting #JAK in #RA Some JAK #dendranib candidates have been found and are being studied Cool technology- need to follow this space #2028 #ACR26 @ACRheum @RheumNow https://t.co/X9E5LzyY0h

Venkat et al. Association of clinical and research antibodies and RA-ILD. There may be a role for extended antibody testing in this group. @RheumNow #ACR26 Abstr#2882 https://t.co/QjPfHhWzdA

Tirzepatide: A Vascular Advantage in RA? #ACR26 Abstract #1424: In 7,944 matched patients with RA and T2DM, tirzepatide was associated with fewer thromboembolic/CV events vs GLP-1 RAs (HR 0.84; 95% CI 0.73–0.98). Promising, but unequal follow-up warrants caution. @RheumNow https://t.co/rT7vTaWY0G

RTX for joint manifestations of SSc? Abs 2158 Study of 80 SSc pts from Uni of Lübeck with documented DAS-CRP treated with RTX suggesting improvement and possible remission by this measure. Concomitant MMF one feature that favored remission? Small, uncontrolled #ACR26 @RheumNow https://t.co/vphSxCfeBJ

Interesting abstract re:clonal hematopoiesis of ), age-related mutations in peripheral blood DNA CHIP was more common among pts w/GCA after correctingf or age and sex (OR 1.51). SRSF2 associated w/large vessel disease; TET2 associated w/cranial phenotype Not ready for clinic, https://t.co/ZEZiob0HWU

Why do pain conditions cluster? #ACR26 Abs# 1551 used Framingham family data to examine heritability of pressure pain threshold and conditioned pain modulation, plus genetic overlap with joint and non-joint pain. Pain sensitization may reflect shared biology. @RheumNow https://t.co/ESVWExCS5Y